Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.48 |
| ▸ | BMP1 | P13497 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518178 | 0.83 | AOC3 (0.54) | AOC3MTNR1AMTNR1BBMP1TAAR1 | |
| SCHEMBL5519402 | 0.82 | ACHE (0.57) | AOC3MTNR1AMTNR1BTAAR1ACHE | |
| SCHEMBL27572230 | 0.76 | MEN1 (0.58) | AOC3ALDH1A1SMN1; SMN2BMP1CHRM1 | |
| SCHEMBL10648377 | 0.76 | AOC3 (0.57) | AOC3ALDH1A1SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL5515766 | 0.73 | OPRM1 (0.53) | AOC3ALDH1A1MTNR1AMTNR1BBMP1 | |
| SCHEMBL5515925 | 0.72 | PTGES (0.53) | AOC3TSHRACHE | |
| SCHEMBL9416588 | 0.72 | HSD17B2 (0.57) | ALDH1A1SMN1; SMN2MTNR1AMTNR1BHDAC1 | |
| SCHEMBL3648866 | 0.72 | ALOX5 (0.58) | AOC3TSHRBMP1 | |
| SCHEMBL6715386 | 0.72 | NPC1 (0.61) | AOC3TSHRKDM4EHPGDACHE | |
| SCHEMBL6417242 | 0.71 | HSD17B2 (0.63) | SMN1; SMN2MTNR1AMTNR1BHPGDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256201-B2 | Selective estrogen receptor-β ligands | ASTRAZENECA AB (SE) | 2007-08-14 | — | — | US | disclosed |
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| EP-1341765-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046164-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ESR2, ESRRA, ESRRB | AOC3 3606/4885ALDH1A1 1692/4885TSHR 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.